Treatments
Prime Minister unveils £48M investment to combat dementia.
After years of campaigning by Alzheimer’s Research UK to make the UK ready for the next generation of dementia treatments, the Prime Minister has announced a £48 million public-private partnership to accelerate dementia research and improve access to clinical trials.
Potential Alzheimer’s treatment, trontinemab, hits the news – how does it work and is it available?
Four years ago, the results of a trial for lecanemab marked a turning point. They showed for the first time that Alzheimer’s disease can be slowed by medication. Not long after, another drug called donanemab followed with similar results. In 2026, there are over 150 drugs in clinical trials across the world. More than ever,…
AAIC 2026: Bold approaches to tackling dementia research
Thousands of dementia researchers gathered in London for AAIC 2026 to share the latest developments in dementia research. From more accessible treatments and emerging blood tests to new approaches to prevention, the conference highlighted the progress being made towards earlier diagnosis, better treatments and a brighter future for people affected by dementia.
New clinical fellowships set to bring better diagnosis and treatments closer for people with dementia
Six new Clinical Fellowships have been awarded to support clinicians in bringing cutting-edge research closer to the people who need it most.
A new era in dementia research: Why the UK must step up or get left behind
Prof Sir John Hardy, Vice President of Alzheimer’s Research UK, outlines how the UK can continue to drive progress towards a cure for dementia.
Turning discoveries into dementia treatments
Our Drug Discovery Alliance unites drug discovery scientists and industry experts to help transform research ideas into new treatments
Global snapshot of Alzheimer’s research offers new hope
Every year, world‑leading dementia researcher Dr Jeffrey Cummings releases a global snapshot of Alzheimer’s trials – and the 2026 update has just been published.
Leaders in the dementia field react to a report with ‘major limitations’ labelling Alzheimer’s drugs as ineffective
A new report suggests that anti-amyloid drugs are ineffective at slowing dementia symptoms. Read more to find out what the research shows.
NHS spending watchdog to review evidence on Alzheimer’s treatments
England’s drugs costs watchdog is to look again at whether new treatments for Alzheimer’s disease should be made available on the NHS.
Our 2026 research conference: a time for collaboration and celebration
Over 700 researchers came together in Manchester for our biggest annual research conference to date. From biomarkers and clinical trial design to the future of dementia prevention, the conversations were wide-ranging, and the buzz in the room has stayed with many of us. The conference opened with a powerful reminder of why this work…
